Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by KAREN H LU and ROBERT COLEMAN.
KAREN H LU
Connection Strength
1.424
ROBERT COLEMAN
  1. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Int J Gynecol Cancer. 2020 11; 30(11):1733-1737.
    View in: PubMed
    Score: 0.196
  2. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res. 2020 02 01; 26(3):581-587.
    View in: PubMed
    Score: 0.183
  3. Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. Gynecol Oncol. 2017 08; 146(2):217-224.
    View in: PubMed
    Score: 0.155
  4. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015 Mar 10; 33(8):930-6.
    View in: PubMed
    Score: 0.132
  5. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.052
  6. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.
    View in: PubMed
    Score: 0.051
  7. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol. 2021 06; 161(3):653-659.
    View in: PubMed
    Score: 0.050
  8. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 03; 160(3):777-785.
    View in: PubMed
    Score: 0.050
  9. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.048
  10. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.
    View in: PubMed
    Score: 0.047
  11. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
    View in: PubMed
    Score: 0.042
  12. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554.
    View in: PubMed
    Score: 0.042
  13. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017 Apr 01; 35(10):1103-1111.
    View in: PubMed
    Score: 0.038
  14. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.
    View in: PubMed
    Score: 0.036
  15. Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. Int J Gynecol Cancer. 2016 May; 26(4):801-6.
    View in: PubMed
    Score: 0.036
  16. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015 Oct; 9(8):1694-703.
    View in: PubMed
    Score: 0.034
  17. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015 Jun; 137(3):553-8.
    View in: PubMed
    Score: 0.033
  18. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79.
    View in: PubMed
    Score: 0.033
  19. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer. 2014 May; 24(4):713-7.
    View in: PubMed
    Score: 0.031
  20. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
    View in: PubMed
    Score: 0.026
  21. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 01; 116(23):5415-9.
    View in: PubMed
    Score: 0.024
  22. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3):467-72.
    View in: PubMed
    Score: 0.024
  23. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.
    View in: PubMed
    Score: 0.022
  24. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 2007 Mar; 109(3):641-6.
    View in: PubMed
    Score: 0.019
  25. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.